UDP-Glucuronosyltransferase 1A7 Genetic Polymorphisms Are Associated with Hepatocellular Carcinoma Risk and Onset Age

Tseng, Chien-Sen; Tang, Kung-Sheng; Lo, Hoi-Wan; Ker, Chen‐Guo; Teng, Hsiu-Chen; Huang, Ching‐Shan

doi:10.1111/j.1572-0241.2005.41857.x

Cited by 54 publications

(34 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Again, low-activity UGT1A7 variants were found to be associated with incidence of HCC in this population. A larger study including 217 HCC patients and 291 controls corroborated these findings when it was reported that the low-activity UGT1A7 polymorphisms correlated with HCC risk (OR 3.06; 95% CI 1.50-6.24) (Tseng et al, 2005). Additionally, in male patients, the age of onset was earlier in the low-activity UGT1A7 genotypes, as against males with the wild-type allele (median age 50 versus 59 years, Po0.05).…”

Section: Hepatocellular Carcinomasupporting

confidence: 71%

Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer

2006

View full text Add to dashboard Cite

The uridine diphosphoglucuronosyltransferases (UGTs) belong to a superfamily of enzymes that catalyse the glucuronidation of numerous endobiotics and xenobiotics. Several human hepatic and extrahepatic UGT isozymes have been characterized with respect to their substrate specificity, tissue expression and gene structure. Genetic polymorphisms have been identified for almost all the UGT family members. A wide variety of anticancer drugs, dietary chemopreventives and carcinogens are known to be conjugated by members of both UGT1A and UGT2B subfamilies. This review examines in detail each UGT isozyme known to be associated with cancer and carcinogenesis. The cancer-related substrates for several UGTs are summarized, and the functionally relevant genetic polymorphisms of UGTs are reviewed. A number of genotype-phenotype association studies have been carried out to characterize the role of UGT pharmacogenetics in several types of cancer, and these examples are discussed here. In summary, this review focuses on the role of the human UGT genetic polymorphisms in carcinogenesis, chemoprevention and cancer risk.

show abstract

Section: Hepatocellular Carcinomasupporting

confidence: 71%

Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer

2006

View full text Add to dashboard Cite

show abstract

“…Recently, we reported that genetic polymorphisms in interleukin-1b and UDP glucuronosyltransferase 1A7 genes were associated with the development of hepatocellular carcinoma in Japanese patients with chronic HCV infection (13,14), which was followed by similar reports by other groups as well (16). We further did a large-scale search of gene polymorphisms associated with the hepatocellular carcinoma development in a much larger population of HCV patients and found that three single nucleotide polymorphisms (SNP) in three genes (SCYB14, GFRA1, and CRHR2) were significantly associated with hepatocellular carcinoma development in Japanese patients with chronic HCV infection (15).…”

mentioning

confidence: 49%

MDM2 Promoter SNP309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C

Dharel

Kato

Muroyama

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: A single nucleotide polymorphism (SNP) in the promoter region of MDM2 gene, SNP309, has recently been shown to be associated with accelerated tumor formation in both hereditary and sporadic cancers in humans. However, the association of SNP309 with hepatocellular carcinoma is unknown. We evaluated the association of SNP309 with the risk of hepatocellular carcinoma development among Japanese patients with chronic hepatitis C virus infection. Experimental Design: We genotyped the SNP309 at the MDM2 promoter in 435 Japanese patients with chronic hepatitis C virus infection, including 187 patients with hepatocellular carcinoma and 48 healthy subjects, using a fluorogenic PCR. Presence of SNP was also confirmed by direct sequencing of the MDM2 promoter region. Results: The proportion of G/G genotype of the SNP309 in patients with hepatocellular carcinoma (33%) was significantly higher than that in patients without hepatocellular carcinoma (23%), with an odds ratio (95% confidence interval) of 2.28 (1.30-3.98). A multivariate analysis revealed that MDM2 SNP309 (G/G versus T/T), age >60 years, male gender, presence of cirrhosis, serum a-fetoprotein >20 Ag/L, and serum albumin <3.2 g/dL were independently associated with the hepatocellular carcinoma development at odds ratio of 2.27, 2.46, 3.08, 4.15, 4.87, and 6.33, respectively. Conclusions: The MDM2 promoter SNP309 is associated with the presence of hepatocellular carcinoma in Japanese patients with chronic hepatitis C.

show abstract

“…UGT1A7 gene. There were six eligible studies including 862 cases and 1546 controls explored the associations between the two SNPs and HCC (Vogel et al 2001;Wang et al 2004;Tseng et al 2005;Borentain et al 2007;Stucker et al 2007;Kong et al 2008). We extracted two polymorphisms' genotype data from the articles to do the meta-analyses.…”

Section: Resultsmentioning

confidence: 99%

Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review

Jin

Xiong

Jing

et al. 2011

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

UDP-Glucuronosyltransferase 1A7 Genetic Polymorphisms Are Associated with Hepatocellular Carcinoma Risk and Onset Age

Abstract: An inverse dose-response relationship was demonstrated between the detoxifying activity of the UGT1A7 genotypes and HCC. Of the male HCC patients, median onset age for those carrying an UGT1A7 low-activity genotype was 9 yr lower than those bearing the high-activity variant.

Cited by 54 publications

References 28 publications

Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer

Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer

MDM2 Promoter SNP309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C

Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review

Contact Info

Product

Resources

About